GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First In-Human Multiple Dose Study in Healthy Subjects With Gut Biopsies
GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First In-Human Multiple Dose Study in Healthy Subjects With Gut Biopsies
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
